Who we are

Financial information

Our management

About us

PEARL

SURF

Traditional Life

Final Expense

Accidental Death

Critical Illness

Specialty Risks

Inforce Blocks

Solutions

Optimum Academy

Media

Wave Underwriting Manuals

The Optimum Tide

Knowledge

Events and webinars

Releases

News

Contact Us

Training modules

Webinars

Case clinics

Learning Series

ORIC - Academy

Optimum Academy Introduction to Medical Topics

Optimum Academy Introduction

<p>Welcome to Heart 101 Module 1 — this quiz will assess your understanding of heart anatomy, circulation, and key diagnostic markers in underwriting evaluation.</p>

The Heart & Blood Vessels

<p>Welcome to Heart 101 Module 2 — this quiz will assess your understanding of coronary artery disease, including coronary anatomy, stenosis, diagnostic testing, and ischemic findings.</p>

Coronary Artery Disease

<p>Welcome to Heart 101 Module 3 — this quiz will assess your understanding of arterial and venous diseases and their implications for mortality risk assessment.</p>

Arterial and Venous Disease

<p>Welcome to Heart 101 Module 4 — this quiz will assess your understanding of hypertension, left ventricular hypertrophy, and related treatment considerations in underwriting decision-making.</p>

High Blood Pressure & Left Ventricular Hypertrophy

<p>Welcome to Heart 101 Module 5 — this quiz will assess your understanding of echocardiographic findings, including valve abnormalities, structural heart conditions, and Doppler flow patterns.</p>

The Echocardiogram & Valvular Disease

<p>Welcome to Heart 101 Module 6 — this quiz will assess your understanding of EKG interpretation, including rhythm analysis, conduction abnormalities, and ischemic indicators.</p>

The Electrocardiogram (EKG) Findings

<p>Welcome to Heart 101 Module 7 — this quiz will assess your understanding of NT-proBNP as a biomarker of cardiac stress and heart function.</p>

NT – proBNP

<section class="text-token-text-primary w-full focus:outline-none [--shadow-height:45px] has-data-writing-block:pointer-events-none has-data-writing-block:-mt-(--shadow-height) has-data-writing-block:pt-(--shadow-height) [&amp;:has([data-writing-block])&gt;*]:pointer-events-auto scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]" dir="auto" data-turn-id="request-WEB:97b0f531-4128-4de3-a020-05f6b20f5296-17" data-testid="conversation-turn-36" data-scroll-anchor="true" data-turn="assistant"><div class="text-base my-auto mx-auto pb-10 [--thread-content-margin:var(--thread-content-margin-xs,calc(var(--spacing)*4))] @w-sm/main:[--thread-content-margin:var(--thread-content-margin-sm,calc(var(--spacing)*6))] @w-lg/main:[--thread-content-margin:var(--thread-content-margin-lg,calc(var(--spacing)*16))] px-(--thread-content-margin)"><div class="[--thread-content-max-width:40rem] @w-lg/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn"><div class="flex max-w-full flex-col gap-4 grow"><div class="min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+&amp;]:mt-1" data-message-author-role="assistant" data-message-id="33f4981e-e044-4b1d-ac76-80aac68fe89d" dir="auto" data-message-model-slug="gpt-5-3" data-turn-start-message="true" tabindex="0"><div class="flex w-full flex-col gap-1 empty:hidden"><div class="markdown prose dark:prose-invert w-full wrap-break-word light markdown-new-styling"><section class="text-token-text-primary w-full focus:outline-none [--shadow-height:45px] has-data-writing-block:pointer-events-none has-data-writing-block:-mt-(--shadow-height) has-data-writing-block:pt-(--shadow-height) [&amp;:has([data-writing-block])&gt;*]:pointer-events-auto scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]" dir="auto" data-turn-id="request-WEB:97b0f531-4128-4de3-a020-05f6b20f5296-17" data-testid="conversation-turn-36" data-scroll-anchor="true" data-turn="assistant"><div class="text-base my-auto mx-auto pb-10 [--thread-content-margin:var(--thread-content-margin-xs,calc(var(--spacing)*4))] @w-sm/main:[--thread-content-margin:var(--thread-content-margin-sm,calc(var(--spacing)*6))] @w-lg/main:[--thread-content-margin:var(--thread-content-margin-lg,calc(var(--spacing)*16))] px-(--thread-content-margin)"><div class="[--thread-content-max-width:40rem] @w-lg/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn"><div class="flex max-w-full flex-col gap-4 grow"><div class="min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+&amp;]:mt-1" data-message-author-role="assistant" data-message-id="33f4981e-e044-4b1d-ac76-80aac68fe89d" dir="auto" data-message-model-slug="gpt-5-3" data-turn-start-message="true" tabindex="0"><div class="flex w-full flex-col gap-1 empty:hidden"><div class="markdown prose dark:prose-invert w-full wrap-break-word light markdown-new-styling"><section class="text-token-text-primary w-full focus:outline-none [--shadow-height:45px] has-data-writing-block:pointer-events-none has-data-writing-block:-mt-(--shadow-height) has-data-writing-block:pt-(--shadow-height) [&amp;:has([data-writing-block])&gt;*]:pointer-events-auto scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]" dir="auto" data-turn-id="request-WEB:97b0f531-4128-4de3-a020-05f6b20f5296-17" data-testid="conversation-turn-36" data-scroll-anchor="true" data-turn="assistant"><div class="text-base my-auto mx-auto pb-10 [--thread-content-margin:var(--thread-content-margin-xs,calc(var(--spacing)*4))] @w-sm/main:[--thread-content-margin:var(--thread-content-margin-sm,calc(var(--spacing)*6))] @w-lg/main:[--thread-content-margin:var(--thread-content-margin-lg,calc(var(--spacing)*16))] px-(--thread-content-margin)"><div class="[--thread-content-max-width:40rem] @w-lg/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn"><div class="flex max-w-full flex-col gap-4 grow"><div class="min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+&amp;]:mt-1" data-message-author-role="assistant" data-message-id="33f4981e-e044-4b1d-ac76-80aac68fe89d" dir="auto" data-message-model-slug="gpt-5-3" data-turn-start-message="true" tabindex="0"><div class="flex w-full flex-col gap-1 empty:hidden"><div class="markdown prose dark:prose-invert w-full wrap-break-word light markdown-new-styling"><section class="text-token-text-primary w-full focus:outline-none [--shadow-height:45px] has-data-writing-block:pointer-events-none has-data-writing-block:-mt-(--shadow-height) has-data-writing-block:pt-(--shadow-height) [&amp;:has([data-writing-block])&gt;*]:pointer-events-auto scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]" dir="auto" data-turn-id="request-WEB:97b0f531-4128-4de3-a020-05f6b20f5296-17" data-testid="conversation-turn-36" data-scroll-anchor="true" data-turn="assistant"><div class="text-base my-auto mx-auto pb-10 [--thread-content-margin:var(--thread-content-margin-xs,calc(var(--spacing)*4))] @w-sm/main:[--thread-content-margin:var(--thread-content-margin-sm,calc(var(--spacing)*6))] @w-lg/main:[--thread-content-margin:var(--thread-content-margin-lg,calc(var(--spacing)*16))] px-(--thread-content-margin)"><div class="[--thread-content-max-width:40rem] @w-lg/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn"><div class="flex max-w-full flex-col gap-4 grow"><div class="min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+&amp;]:mt-1" data-message-author-role="assistant" data-message-id="33f4981e-e044-4b1d-ac76-80aac68fe89d" dir="auto" data-message-model-slug="gpt-5-3" data-turn-start-message="true" tabindex="0"><div class="flex w-full flex-col gap-1 empty:hidden"><div class="markdown prose dark:prose-invert w-full wrap-break-word light markdown-new-styling"><p data-start="0" data-end="168" data-is-last-node data-is-only-node>Welcome to Heart 101 Module 8 — this quiz will assess your understanding of coronary artery calcium (CAC) scoring, subclinical atherosclerosis, and risk prediction.</p></div></div></div></div></div></div></section></div></div></div></div></div></div></section></div></div></div></div></div></div></section></div></div></div></div></div></div></section>

Coronary Artery Calcium Scores

Heart 101

<p>Welcome to Diabetes 101 Module 1 — this quiz focuses on diabetes mellitus, including glucose and A1C thresholds, glycemic control, and blood sugar regulation.</p>

Introduction

<p>Welcome to Diabetes 101 Module 2 — this quiz focuses on diabetes types, including Type 1, Type 2, and gestational diabetes, along with insulin function and A1C control.</p>

Types

<p>Welcome to Diabetes 101 Module 3 — this quiz focuses on treatment strategies for Type 1, Type 2, and gestational diabetes, including insulin therapy, medication classes, and A1C control.</p>

Treatments

<p>Welcome to Diabetes 101 Module 4 — this quiz focuses on diabetes-related complications, including cardiovascular disease, nephropathy, retinopathy, and neuropathy.</p>

Complications

Diabetes 101

<p>Welcome to Pulmonary 101 Module 1 — this quiz focuses on pulmonary anatomy, gas exchange, obstructive and restrictive lung diseases, infections, and oxygen saturation.</p>

Introduction to Pulmonary Disease

<p>Welcome to Pulmonary 101 Module 2 — this quiz focuses on pulmonary function test metrics, including FEV1, FVC, the FEV1/FVC ratio, spirometry patterns, and bronchodilator response.</p>

Pulmonary Function Studies (PFTs)

<p>Welcome to Pulmonary 101 Module 3 — this quiz focuses on COPD, including emphysema and chronic bronchitis, airflow limitation, key clinical markers, and treatment approaches.</p>

Chronic Obstructive Pulmonary Disease (COPD)

<p>Welcome to Pulmonary 101 Module 4 — this quiz focuses on asthma, including airway inflammation, bronchoconstriction, triggers, variable pulmonary function tests, and treatment response.</p>

Understanding Asthma

<p>Welcome to Pulmonary 101 Module 5 — this quiz focuses on pulmonary medications, including inhaled delivery methods, beta-2 agonists, corticosteroids, anticholinergics, and proper device use.</p>

Pulmonary Medications

<p>Welcome to Pulmonary 101 Module 6 — this quiz focuses on lung cancer, including tobacco exposure, cancer type, stage at diagnosis, lung nodules, and Fleischner guidelines.</p>

Lung Cancer

<p>Welcome to Pulmonary 101 Module 7 — this quiz focuses on tuberculosis, including latent and active forms, drug resistance, treatment compliance, and sarcoidosis.</p>

Tuberculosis & Sarcoidosis

<p>Welcome to Pulmonary 101 Module 8 — this quiz focuses on interstitial lung disease, including inflammation and fibrosis, causes, diagnostic approaches, and treatment strategies.</p>

Interstitial Lung Disease

<p>Welcome to Pulmonary 101 Module 9 — this quiz focuses on obstructive sleep apnea, including airway obstruction, polysomnography, AHI/RDI severity, oxygen desaturation, and treatment approaches.</p>

Obstructive Sleep Apnea (OSA)

Pulmonary 101

Oncology 101 - Understanding Ratings

Oncology 101 - Introduction To Cancer

Oncology 101

<p>Welcome to Breast Cancer 101 Module 1 — this quiz focuses on early detection, imaging modalities, BI-RADS classification, and individual risk factors.</p>

Breast Cancer 101 - Breast Cancer Screening & Testing Modalities

<section class="text-token-text-primary w-full focus:outline-none [--shadow-height:45px] has-data-writing-block:pointer-events-none has-data-writing-block:-mt-(--shadow-height) has-data-writing-block:pt-(--shadow-height) [&amp;:has([data-writing-block])&gt;*]:pointer-events-auto scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]" dir="auto" data-turn-id="request-WEB:97b0f531-4128-4de3-a020-05f6b20f5296-27" data-testid="conversation-turn-56" data-scroll-anchor="true" data-turn="assistant"><div class="text-base my-auto mx-auto pb-10 [--thread-content-margin:var(--thread-content-margin-xs,calc(var(--spacing)*4))] @w-sm/main:[--thread-content-margin:var(--thread-content-margin-sm,calc(var(--spacing)*6))] @w-lg/main:[--thread-content-margin:var(--thread-content-margin-lg,calc(var(--spacing)*16))] px-(--thread-content-margin)"><div class="[--thread-content-max-width:40rem] @w-lg/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn"><div class="flex max-w-full flex-col gap-4 grow"><div class="min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+&amp;]:mt-1" data-message-author-role="assistant" data-message-id="131b10ff-11b9-4b1f-9f19-4b9d1e7f3d6f" dir="auto" data-message-model-slug="gpt-5-3" data-turn-start-message="true" tabindex="0"><div class="flex w-full flex-col gap-1 empty:hidden"><div class="markdown prose dark:prose-invert w-full wrap-break-word light markdown-new-styling"><section class="text-token-text-primary w-full focus:outline-none [--shadow-height:45px] has-data-writing-block:pointer-events-none has-data-writing-block:-mt-(--shadow-height) has-data-writing-block:pt-(--shadow-height) [&amp;:has([data-writing-block])&gt;*]:pointer-events-auto scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]" dir="auto" data-turn-id="request-WEB:97b0f531-4128-4de3-a020-05f6b20f5296-27" data-testid="conversation-turn-56" data-scroll-anchor="true" data-turn="assistant"><div class="text-base my-auto mx-auto pb-10 [--thread-content-margin:var(--thread-content-margin-xs,calc(var(--spacing)*4))] @w-sm/main:[--thread-content-margin:var(--thread-content-margin-sm,calc(var(--spacing)*6))] @w-lg/main:[--thread-content-margin:var(--thread-content-margin-lg,calc(var(--spacing)*16))] px-(--thread-content-margin)"><div class="[--thread-content-max-width:40rem] @w-lg/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn"><div class="flex max-w-full flex-col gap-4 grow"><div class="min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+&amp;]:mt-1" data-message-author-role="assistant" data-message-id="131b10ff-11b9-4b1f-9f19-4b9d1e7f3d6f" dir="auto" data-message-model-slug="gpt-5-3" data-turn-start-message="true" tabindex="0"><div class="flex w-full flex-col gap-1 empty:hidden"><div class="markdown prose dark:prose-invert w-full wrap-break-word light markdown-new-styling"><p data-start="0" data-end="177" data-is-last-node data-is-only-node>Welcome to Breast Cancer 101 Module 2 — this quiz focuses on histologic types, including in situ and invasive lesions, and the role of sentinel lymph node biopsy in staging.</p></div></div></div></div></div></div></section></div></div></div></div></div></div></section>

Breast Cancer 101: Types of Breast Cancer

<p>Welcome to Breast Cancer 101 Module 3 — this quiz focuses on tumor grade, ER status, HER2 status, and the Optimum Re breast cancer risk score.</p>

Breast Cancer 101 - The New Underwriting "RISK SCORE" Feature

<p>Welcome to Breast Cancer 101 Module 4 — this quiz focuses on TNM stage, risk score, nodal involvement, age, and time since treatment in final underwriting outcomes</p>

Breast Cancer 101 - Staging & Rating Breast Cancer

Breast Cancer 101

<p>Welcome to Prostate Cancer 101 Module 1 — this quiz focuses on PSA testing, screening guidelines, biopsy procedures, Gleason scoring, and prostate cancer biomarkers.</p>

Prostate Cancer 101 - PSA Testing & Diagnosis of Prostate Cancer

<p>Welcome to Prostate Cancer 101 Module 2 — this quiz focuses on TNM staging, Gleason scores, Grade Groups, treatment options, and PSA trends.</p>

Prostate Cancer 101 - Staging, Treatments, And Ratings For Prostate Cancer

Prostate Cancer 101

<section class="text-token-text-primary w-full focus:outline-none [--shadow-height:45px] has-data-writing-block:pointer-events-none has-data-writing-block:-mt-(--shadow-height) has-data-writing-block:pt-(--shadow-height) [&amp;:has([data-writing-block])&gt;*]:pointer-events-auto scroll-mt-(--header-height)" dir="auto" data-turn-id="d6ec9ce1-e115-4c4f-8b60-b37b899f1244" data-testid="conversation-turn-67" data-scroll-anchor="false" data-turn="user"><section class="text-token-text-primary w-full focus:outline-none [--shadow-height:45px] has-data-writing-block:pointer-events-none has-data-writing-block:-mt-(--shadow-height) has-data-writing-block:pt-(--shadow-height) [&amp;:has([data-writing-block])&gt;*]:pointer-events-auto scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]" dir="auto" data-turn-id="request-WEB:97b0f531-4128-4de3-a020-05f6b20f5296-33" data-testid="conversation-turn-68" data-scroll-anchor="true" data-turn="assistant"><div class="text-base my-auto mx-auto pb-10 [--thread-content-margin:var(--thread-content-margin-xs,calc(var(--spacing)*4))] @w-sm/main:[--thread-content-margin:var(--thread-content-margin-sm,calc(var(--spacing)*6))] @w-lg/main:[--thread-content-margin:var(--thread-content-margin-lg,calc(var(--spacing)*16))] px-(--thread-content-margin)"><div class="[--thread-content-max-width:40rem] @w-lg/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn"><div class="flex max-w-full flex-col gap-4 grow"><div class="min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+&amp;]:mt-1" data-message-author-role="assistant" data-message-id="de0fb137-6c30-40bb-8523-aeca000b6594" dir="auto" data-message-model-slug="gpt-5-3" data-turn-start-message="true" tabindex="0"><div class="flex w-full flex-col gap-1 empty:hidden"><div class="markdown prose dark:prose-invert w-full wrap-break-word light markdown-new-styling"><p data-start="0" data-end="209" data-is-last-node data-is-only-node>Welcome to Rheumatoid Arthritis 101 Module 1 — this quiz focuses on rheumatoid arthritis as a systemic autoimmune condition and the role of chronic inflammation in cardiovascular and pulmonary involvement.</p></div></div></div></div></div></div></section></section>

Rheumatoid Arthritis 101 - RA is an Inflammatory Disease

<p>Welcome to Rheumatoid Arthritis 101 Module 2 — this quiz focuses on inflammation control using DMARDs and biologics, along with disease control, inflammatory markers, and infection screening compliance.</p>

Rheumatoid Arthritis 101 - Treatment for RA

Rheumatoid Arthritis 101

<p>Welcome to Cholesterol 101 Module 1 — this quiz focuses on lipoprotein transport, including LDL, lipoprotein(a), and HDL in atherosclerotic risk.</p>

Cholesterol 101 - Cholesterol and it's Delivery Vehicle

<p>Welcome to Cholesterol 101 Module 2 — this quiz focuses on ApoB-containing particles, including Lp(a), and their role in atherogenic risk.</p>

Cholesterol 101 - Lipoproteins

<p>Welcome to Cholesterol 101 Module 3 — this quiz focuses on advanced lipid metrics, including apoB, non-HDL cholesterol, and lipid discordance.</p>

Cholesterol 101 - Underwriting Lipoprotein Levels

<p>Welcome to Cholesterol 101 Module 4 — this quiz focuses on lipid-lowering therapies, including statins, ezetimibe, PCSK9 inhibitors, and emerging treatments targeting lipoprotein(a).</p>

Cholesterol 101 - Treatment of Elevated Cholesterol

<p>Welcome to Cholesterol 101 Module 5 — this quiz focuses on comprehensive risk assessment, including particle number, genetic factors, and advanced lipid testing.</p>

Cholesterol 101 - Cholesterol Risk Factors

Cholesterol 101

<p>Welcome to Lab Trending 101 Module 1 — this quiz focuses on large-scale data analytics, population-level shifts, and predictive risk signals</p>

Lab Trending 101 - What is Lab Trending?

<p>Welcome to Lab Trending 101 Module 2 — this quiz focuses on lab variations, including demographic, geographic, and procedural influences, and the role of longitudinal and comparative analysis.</p>

Lab Trending 101 - Lab Value & Paramed Exam Trends

Lab Trending 101

<p>Welcome to A New Alcohol Marker 101 Module 1 — this quiz focuses on traditional alcohol screening tools, including APS history, liver function tests, MCV, HDL, and CDT, and introduces PEth as a direct ethanol marker.</p>

A New Alcohol Marker 101 - Our Current Arsenal For Detecting Alcohol Use

<p>Welcome to A New Alcohol Marker 101 Module 2 — this quiz focuses on PEth as a direct biomarker of ethanol ingestion, including its formation, specificity, and relevance to red blood cell lifespan.</p>

A New Alcohol Marker 101 - PEth–Phosphatidylethanol

<p>Welcome to A New Alcohol Marker 101 Module 3 — this quiz focuses on PEth formation, detection window, threshold levels, and gender-related differences.</p>

A New Alcohol Marker 101 - An Insider's Look at the PEth Test

<p>Welcome to A New Alcohol Marker 101 Module 4— this quiz focuses on EtG and EtS urine biomarkers, including detection windows, dual positivity, and recent ethanol consumption.</p>

A New Alcohol Marker 101 - Ethyl Glucuronide & Ethyl Sulfate

A New Alcohol Marker 101

<p>Welcome to Financials 101 Module 1 — this quiz focuses on insurable interest, including personal, business, and charitable relationships, financial loss, and beneficiary considerations.</p>

Financial 101 - Insurable Interest - Intro to Financial

<p>Welcome to Financials 101 Module 2 — this quiz focuses on income replacement, including earned vs. unearned income, income multiples, and coverage considerations.</p>

Financial 101- Income Replacement

<p>Welcome to Financials 101 Module 3 — this quiz focuses on estate conservation, including net worth, liquidity needs, assets and liabilities, and estate multiples.</p>

Financial 101 - Estate Conservation

<p>Welcome to Financials 101 Module 4 — this quiz focuses on business coverage, including key individuals, ownership structures, insurable interest, and loan obligations.</p>

Financial 101 - Business Coverage - The Basics

<p>Welcome to Financials 101 Module 5 — this quiz focuses on farm valuation, including income, assets, liabilities, ownership percentage, and financial documentation.</p>

Financial 101 - Farm Valuation

Financials 101 - Juvenile Insurance

Financials 101 (L2) - Tax Forms

Financials 101 (L2) - Trusts

Financials 101

<p>Welcome to Ketamine 101 Module 1 — this quiz focuses on serotonin, dopamine, oxytocin, endorphins, neurotransmitter pathways, and SSRI/SNRI mechanisms.</p>

Ketamine 101 - Brain Hormones 

<p>Welcome to Ketamine 101 Module 2 — this quiz focuses on ketamine therapy, including NMDA receptor blockade, glutamate activity, neuroplasticity, and treatment approaches.</p>

Ketamine 101 - Ketamine for Psych Impairments

<p>Welcome to Ketamine 101 Module 3 — this quiz focuses on ketamine’s effects on the glutamate system, including NMDA receptor blockade, AMPA receptor activation, and synaptogenesis.</p>

Ketamine 101 - How Does Ketamine Work?

Ketamine 101

<p>Welcome to PrEP &amp; HIV Module 1 — this quiz focuses on pre-exposure prophylaxis (PrEP), including antiretroviral therapy, adherence, and risk reduction.</p>

PrEP & HIV 101 - PrEP

<p>Welcome to PrEP &amp; HIV Module 2 — this quiz focuses on HIV as a retrovirus, including reverse transcriptase, RNA-to-DNA integration, CD4 cell invasion, and antiretroviral therapy.</p>

PrEP & HIV 101 - Retroviruses

<p>Welcome to PrEP &amp; HIV Module 3 — this quiz focuses on antiretroviral therapy regimens, including combination treatments, viral suppression, undetectable viral load, and CD4 counts</p>

PrEP & HIV 101 - HIV Medications

<p>Welcome to PrEP &amp; HIV Module 4 — this quiz focuses on underwriting criteria for HIV-positive applicants, including viral load, CD4 counts, treatment adherence, and comorbidities.</p>

PrEP & HIV 101 - Underwriting HIV Positive Applicants

<p>Welcome to PrEP &amp; HIV Module 5 — this quiz focuses on HIV co-infections, including tuberculosis, syphilis, laboratory testing, and related risk factors.</p>

Careers

Countries:

Group sites

Follow us: